



TABLE OF CONTENT

COVER PAGE.....	i
RATIFICATION PAGE.....	ii
ASSERTION.....	iii
ACKNOWLEDGEMENT.....	iv
TABLE OF CONTENT.....	v
LIST OF TABLES.....	vii
LIST OF FIGURES.....	viii
ABSTRACT.....	ix
CHAPTER I.....	1
1.1 Study Background.....	1
1.2 Problem Formulation.....	3
1.3 Objectives of The Study.....	3
1.4 Study Authenticity.....	3
1.5 Study Benefit.....	5
1.5.1 For Researcher.....	5
1.5.2 For Practitioner.....	5
1.5.3 For Patient.....	5
CHAPTER II.....	6
2.1 Literature Review.....	6
2.1.1 Chronic Hepatitis B.....	6
2.1.1.1 Definition of Chronic Hepatitis B.....	6
2.1.1.3 Epidemiology of Chronic Hepatitis B.....	6
2.1.1.2 Pathophysiology of Chronic Hepatitis B.....	7
2.1.1.4 Diagnosis and Evaluation of Chronic Hepatitis B.....	8
2.1.1.5 Treatment of Chronic Hepatitis B.....	9
2.1.2 Liver Fibrosis.....	10
2.1.2.1 Definition of Liver Fibrosis.....	10
2.1.2.2 Staging for Liver Fibrosis.....	11
2.1.2.4 Non-invasive Test to Assess Liver Fibrosis.....	13
2.1.2.5 Liver Fibrosis Changes During Antiviral Treatment.....	15
2.1.3 Monitoring of Treatment Response.....	15
2.1.3.1 Definition of Treatment Response.....	15
2.1.3.2 HBV Quantitative DNA.....	16
2.1.3.2 Relation of HBV DNA with Other Markers.....	16
2.3 Conceptual Framework.....	19
2.4 Hypothesis.....	19
CHAPTER III.....	20
3.1 Study Design.....	20
3.2 Time and Study Setting.....	20



3.3 Study Population.....	20
3.4 Study Subject.....	20
3.5 Study Sample.....	21
3.6 Study Variables.....	21
3.8 Study Flow.....	23
3.10 Ethical Consideration.....	23
CHAPTER IV.....	24
4.1 Results.....	24
4.1.1 Characteristic of Research Subject.....	24
4.1.2 Normality Test.....	26
4.1.3 Correlation Analysis of Therapy Duration with Viral load.....	27
4.1.4 Correlation Analysis of Therapy Duration with Liver Stiffness Measurement using Transient Elastography (kPa).....	28
4.1.5 Correlation Analysis of Therapy Duration with Fibrosis Stage.....	29
4.1.6 Analysis of Other Independent Variables with Therapy Duration.....	29
4.1.6.1 Age.....	29
4.1.6.2 Gender.....	30
4.1.6.3 HBeAg Status.....	30
4.1.6.3.1 Relation between Viral Load and HBeAg Status.....	30
4.1.6.4 Liver Function Test.....	31
4.1.6.5 Type of Therapy.....	31
4.1.6.6 Total Comorbidities.....	32
4.1.7 Multivariate Analysis.....	32
4.1.8 Multiple Linear Model on Therapy Duration.....	33
4.2 Discussion.....	34
4.3 Research Limitation.....	37
CHAPTER V.....	38
5.1 Conclusions.....	38
5.2 Recommendations.....	38
REFERENCES.....	39



LIST OF TABLES

Table 1. Study Authenticity.....	4
Table 2. Phases of Chronic HBV Infection.....	9
Table 3. Summary of Guidelines on Treatment Initiation Recommendations for Antiviral Therapy.....	10
Table 4. Fibrosis Grading System.....	12
Table 5. AASLD fibrosis classification.....	12
Table 6. Non-invasive test to assess to assess liver fibrosis.....	14
Table 7. Operation Definition.....	22
Table 8. Baseline Characteristics.....	25
Table 9. Normality Test of Numerical Variable.....	26
Table 10. Normality Test of Gender.....	26
Table 11. Normality Test of HBeAg status.....	27
Table 12. The Normality Test of Therapy Type.....	27
Table 13. Correlation Analysis of Therapy Duration with Viral Load Result.....	27
Table 14. Correlation Analysis of Therapy Duration with Transient Elastography (kPa) Result.....	28
Table 15. Therapy Duration Difference Based on Fibrosis Stage.....	29
Table 16. Correlation of Therapy Duration with Age.....	29
Table 17. Therapy Duration Difference Based on Gender.....	30
Table 18. Therapy Duration Difference Based on HBeAg Status.....	30
Table 19. Viral Load Difference Based on HBeAg Status.....	30
Table 20. Therapy Duration Difference Based on Liver Function Test.....	31
Table 21. Therapy Duration Difference Based on Therapy Type.....	31
Table 22. Therapy Duration Difference Based on Total Comorbidities.....	32
Table 23. Linear Regression Test Result on Therapy Duration Effect.....	32



LIST OF FIGURES

Figure 1. Scatter Plot of Therapy Differences based on Viral Load..... 28